Copyright
©The Author(s) 2022.
World J Crit Care Med. Jan 9, 2022; 11(1): 48-57
Published online Jan 9, 2022. doi: 10.5492/wjccm.v11.i1.48
Published online Jan 9, 2022. doi: 10.5492/wjccm.v11.i1.48
Remdesivir (n = 20) | Control (n = 25) | |
Mean age (yr) | 64.20 (± 15.16) | 68.32 (± 12.67) |
Age groups in years (n, %) | ||
18-40 | 2 (10) | 1 (4) |
41-64 | 5 (25) | 7 (28) |
Above 65 | 13 (65) | 17 (68) |
Females (n, %) | 11 (55) | 12 (48) |
Race or ethnic group (n, %) | ||
White or Caucasian | 9 (45) | 12 (48) |
Hispanic | 5 (25) | 9 (36) |
Black or African American | 2 (10) | 2 (8) |
Other | 4 (20) | 2 (8) |
Tobacco use (n, %) | 11 (55) | 14 (56) |
Diabetes mellitus (n, %) | 13 (65) | 20 (80) |
Hypertension (n, %) | 19 (95) | 24 (96) |
Coronary artery disease/peripheral vascular disease (n, %) | 8 (40) | 9 (36) |
Congestive heart failure (n, %) | 10 (50) | 12 (48) |
History of lung disease- no. (%) | 6 (30) | 9 (36) |
Obesity (BMI>30 kg/m2) (n, %) | 8 (40) | 12 (48) |
Arrhythmia (n, %) | 6 (30) | 9 (36) |
Length of stay - d (± SD) | 13.00 (± 7.35) | 12.16 (± 8.38) |
Treatment (n, %) | ||
Corticosteroids | 20 (100) | 17 (68) |
Antibiotics | 13 (65) | 13 (52) |
Therapeutic anticoagulation | 9 (45) | 11 (44) |
Outcome: Max O2 | Outcome: Ventilation | Outcome: Time to Mortality | |||||||
Variable | PE | X2 (1) | p | PE | X2 (1) | P value | PE | X2 (1) | P value |
Age | 0.32 | 3.25 | 0.0712 | 0.04 | 0.56 | 0.4562 | 0.05 | 1.75 | 0.1860 |
Tobacco use | 8.59 | 3.82 | 0.0507 | 1.29 | 0.91 | 0.3399 | -0.89 | 0.91 | 0.3398 |
Female Sex | -9.49 | 5.43 | 0.0198 | -2.94 | 3.80 | 0.0511 | 0.05 | < 0.01 | 0.9529 |
Black, Hispanic, and Other races | 7.02 | 2.69 | 0.1011 | 2.14 | 1.96 | 0.1614 | 1.18 | 1.91 | 0.1672 |
Obesity | 5.35 | 1.36 | 0.2444 | 1.46 | 0.74 | 0.3904 | 0.32 | 0.16 | 0.6932 |
Diabetes | -20.59 | 5.21 | 0.0224 | -4.06 | 3.61 | 0.0575 | -4.17 | 9.25 | 0.0024 |
High d dimers | -21.50 | 2.22 | 0.1358 | -0.01 | < 0.01 | 0.9971 | -5.86 | 7.41 | 0.0065 |
Remdesivir | -25.93 | 6.65 | 0.0099 | -28.52 | 22.98 | < 0.0001 | -5.03 | 7.42 | 0.0065 |
D dimers | Diabetes | Condition | Mean | Z | P value | Cohen's d |
Outcome: Max O2 | ||||||
High | Yes | Remdesivir | 28.80 | -0.75 | 0.2260 | 0.43 |
Control | 36.81 | |||||
No | Remdesivir | 46.23 | 2.38 | 0.0087 | 1.76 | |
Control | 13.22 | |||||
Low | Yes | Remdesivir | 13.99 | -0.33 | 0.3712 | 0.09 |
Control | 15.72 | |||||
No | Remdesivir | 8.79 | -2.06 | 0.0199 | 1.38 | |
Control | 34.72 | |||||
Outcome: Probability of being on a ventilator | ||||||
D dimers | Diabetes | Condition | % on ventilator | Z | p | Risk ratio |
High | Yes | Remdesivir | 6.16 | -1.21 | 0.1125 | 0.11 |
Control | 55.34 | |||||
No | Remdesivir | 67.92 | -0.07 | 0.4708 | 0.90 | |
Control | 75.47 | |||||
Low | Yes | Remdesivir | 8.22 | 0.27 | 0.3955 | 1.62 |
Control | 5.07 | |||||
No | Remdesivir | 0.00 | -4.45 | < 0.0001 | 0.00 | |
Control | 75.66 | |||||
Outcome: Time to mortality | ||||||
D dimers | Diabetes | Condition | Hazard ratio | Z | p | Risk ratio |
High | Yes | Remdesivir | -3.13 | 0.11 | 0.4570 | 5.78 |
Control | -4.92 | |||||
No | Remdesivir | -5.98 | -0.02 | 0.4930 | 0.89 | |
Control | -5.86 | |||||
Low | Yes | Remdesivir | -4.84 | -0.12 | 0.4512 | 0.52 |
Control | -4.17 | |||||
No | Remdesivir | -5.03 | -2.72 | 0.0032 | 0.01 | |
Control | 0.00 |
- Citation: Selvaraj V, Lal A, Finn A, Tanzer JR, Baig M, Jindal A, Dapaah-Afriyie K, Bayliss G. Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease. World J Crit Care Med 2022; 11(1): 48-57
- URL: https://www.wjgnet.com/2220-3141/full/v11/i1/48.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v11.i1.48